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Quick Response Code: INTRODUCTION
Low-grade gliomas (LGG) have been described according to the World Health Organization 
(WHO), as Grades I and II.[7] Among these LGGs, the most common primary brain tumor is 
PA, accounting for 5.1% of all primary brain and central nervous system gliomas, and are 
described as relatively benign Grade I neoplasms.[7,9] It is the most prevalent primary brain 
tumor among children age 0–19 years, representing 15.3% of all cases.[9] Among children age 
0–14 years, PAs have an annual age-adjusted incidence rate of 1.01 (per 100,000) that significantly 
decreases (0.28/100,000) in adolescents and young adults (age 15–30 years).[9] PAs in children 
ABSTRACT
Background: Low-grade gliomas (LGG) are described by the World Health Organization as Grades I and II. 
Among LGGs, the most common primary brain tumor is pilocytic astrocytoma (PA) and carries an excellent 
prognosis when treated with complete surgical resection. Cases, in which this is not possible, are associated with 
less favorable outcomes and worse progression-free survival.
Case Description: is report describes a case of a 22-year-old male, who presented with progression of a 
primary brainstem tumor previously treated with stereotactic radiosurgery and chemotherapy. Patient underwent 
surgical exploration and was diagnosed with juvenile PA, but debulking was limited by the very dense and fibrous 
tumor. Complete surgical resection was not possible at this time. Despite efforts to treat with chemotherapy, the 
patient presented a year later with clinical deterioration and severe neurologic deficits, prompting surgical re-
exploration. During the second operation, the tumor was found to have undergone very significant softening in 
consistency, allowing for gross total resection (GTR) 
Conclusion: Aggressive treatment of brainstem LGG should be pursued whenever possible, given its generally 
favorable prognosis. Repeat microsurgical resection, even with a different approach, might be reasonable and 
safe. Finally, chemotherapy may be associated with changes in the tumor consistency that can render previously 
unresectable lesions amenable to successful aggressive resection.
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most commonly occur in the cerebellum, optic pathway/
hypothalamic region, and supratentorial hemispheres but 
less frequently may occur in the brainstem and spinal cord.[2] 
PAs commonly arise sporadically but there is an increased 
risk occurrence in the optic pathway in patients with 
neurofibromatosis Type 1.[3]
PAs are typically well-defined tumors with cystic formation 
occurring within the tumor or around the tumor with associated 
solid nodule.[3] Histopathologically, PAs demonstrate a biphasic 
growth pattern with areas of highly fibrillated cells mixed with 
loose microcystic component accompanied by Rosenthal fibers 
and eosinophilic granular bodies.[3] Microvascular proliferation 
is common but does not indicate malignancy like in diffuse 
high-grade gliomas.[3] Recently, genetic alterations in the 
mitogen-activated protein kinase pathway of PAs have been 
described in literature with the most common alteration being 
a fusion between KIAA1549 and BRAF.[3]
While PAs are considered to have an excellent prognosis with 
overall 10-year survival reported over 90%, tumors where 
complete surgical resection is unable to be carried out have 
less favorable progression-free survival (PFS) and overall 
survival.[3,9] Primary treatment of these tumors is surgery, 
but radiotherapy and chemotherapy may be indicated in 
cases with incomplete resection or contraindication to 
surgery.[3] Among reported brainstem LGGs treated with 
surgical resection or chemotherapy, there is a clear positive 
correlation with extent of surgical resection and PFS [Table 1]. 
For example, Ahmed et al. describes 21 patients who received 
gross total resection (GTR) or subtotal resection (STR) with 
5-year overall survival of 85%, while Klimo et al. reported 9 
patients who received GTR with 5-year PFS at 75%.[1, 6]
However, the repeat microsurgical resection of partially 
resected tumors that have been treated with chemotherapy 
resulting in gross total resection (GTR) has not been 
previously reported. Here, we present a case of a 22-year-old 
male with an initially unresectable brainstem LGG treated 
with vincristine and carboplatin, subsequently undergoing 
changes in consistency allowing for GTR on repeat surgery. 
CASE PRESENTATION 
History
On March 2015, a 22-year-old right-handed male with a 
2 month history of right sided weakness and numbness was 
diagnosed with a primary brainstem tumor on MRI. He was 
empirically treated with temozolomide, bevacizumab, and 
stereotactic radiosurgery (SRS). Six months later, while stable 
disease was noted on brain MRI, the patient was also treated 
with an additional hypo-fractionated course (~50Gy in 25 
fractions over 2 months) of involved field radiation. 
Patient received empiric chemotherapy and radiation therapy 
for 21 months and follow-up brain MRI on December 
2016 revealed a stable, necrotic left midbrain mass lesion 
Table 1: Summary of previously reported brainstem low-grade glioma managed with surgical resection or chemotherapy.
Citation Patient Age Surgical Resection Chemotherapy Outcomes 
Upadhyaya  
et al., 2017
25 patients (median 
age 6 years old) 
GTR: 4 patients
NTR or less: 21 patients 
Adjuvant therapy: 10 
patients 
GTR: 10 year PFS at 100% (4/4)
Entire cohort: 10 year PFS at 71% 
Ronghe  
et al., 2010 
16 patients (median 
age 4.2 years old) 
Partial or STR: 14 patients Vincristine and 
Carboplatin: 16 patients




28 patients (median 
age 7.8 years old) 
GTR or resection with linear 
enhancement: 12 patients
Solid residual tumor or 
biopsy: 16 patients
Adjuvant therapy: 2 
patients
GTR or resection with linear 
enhancement: 5 year PFS at 74%
Solid residual tumor or biopsy: 5 year 
PFS at 19% 
Lundar  
et al., 2014
15 patients (median 
age 6 years old) 
Primary tumor resection: 15 
patients
Repeat resection: 6 patients 
Adjuvant therapy: 4 
patients
Median follow up of 8 years with 80% 
survival rate (12/15) 
Ahmed  
et al., 2014[1]
48 patients (median 
age 12 years old) 
GTR: 4 patients 
STR: 17 patients
Biopsy: 27 patients 
Procarbazine, 
Lomustine, and 




Median follow-up of 6 years
GTR or STR: 5-year overall survival 
85% 
Biopsy: 5-year overall survival 50% 
Entire cohort: 5-year overall survival 
67% 
Klimo et al., 
2013[6]
52 patients (median 
age 6.5 years old) 
GTR: 9 patients 
NTR: 17 patients 
STR: 9 patients
Biopsy: 17 patients 
Adjuvant chemo 
and radiotherapy: 27 
patients 
GTR: 5-year PFS at 75% 
NTR: 5-year PFS at 25.7% 
STR: 5-year PFS at 33.3% 
Entire cohort: 5-year overall survival 
98% 
GTR: Gross total resection, PFS: Progression-free survival, NTR: Near total resection, STR: Subtotal resection 
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measuring 2.5 × 2.1 × 1.8 cm with subacute hemorrhage in 
the inferior posterior margin [Figure 1].
Nearly 2 years after the initial diagnosis, the patient presented 
to the clinic with progressively worsening gait instability 
and left greater than right weakness. Additional symptoms 
included transient confusion with malaise and dizziness. 
Brain MRI at this time revealed progression at medial and 
inferior margins along with interval mild ventriculomegaly 
consistent with obstructive hydrocephalus [Figure  2]. 
Decision was made to place the shunt and resect the tumor in 
a two-stage procedure during the same admission.
First operation – VP shunt placement and partial tumor 
resection/biopsy
e patient underwent an uneventful right occipital 
ventriculoperitoneal shunt placement with utilization of 
volumetric image guidance and laparoscopic assistance.
e following day, left posterior temporal-occipital craniotomy 
was performed with an intention to obtain tissue for diagnosis 
and remove as much of the brainstem tumor as safely as possible. 
Volumetric image guidance, microscope, neuro-monitoring, 
and intraoperative MRI were utilized. e brainstem lesion 
was approached through the posterior temporal-occipital 
supratentorial plane with sectioning of the tentorium to widen 
the exposure. e inferior posterior temporal gyrus was 
partially resected, allowing mobilization and preservation of 
the vein of Labbe. e midbrain was entered through the lateral 
mesencephalic safe entry zone. e tumor itself was very firm 
and moderately vascular. Usual microsurgical tools, including 
ultrasonic aspirator, were inefficient.
e tumor’s firm consistency did not allow us to remove 
much of the lesion. e outer portions of the mass were 
very fibrous and could not be mobilized. Progress was 
very slow. e remaining tumor was “hard as a rock” in 
consistency, and surgical manipulation would move it as a 
Figure 1: Initial brain MRI: (a) Axial T1 image with contrast; (b) coronal FLAIR and (c) coronal T1 with contrast images, showing large left 
midbrain-pontine lesion at the time of stereotactic radiosurgery.
cba
Figure 2: Two years after stereotactic radiosurgery and first round of chemotherapy: (a) Brain CT showing hemorrhage in the dorsal aspect 
of the tumor. Brain MRI with contrast: (b) Axial T1 image demonstrating the lesion in the left brainstem and prominent temporal horns 
(arrows), suggestive of an obstructive hydrocephalus; (c) sagittal T1 image showing ring-enhancing mass.
cba
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single block, distorting the entire brainstem. Considering the 
circumstances, it was felt that the safest choice would be to 
stop further dissection/tumor removal. Intraoperative MRI 
showed an approximately 40% decrease in tumor volume, but 
the peripherally enhancing capsule of the tumor remained 
unchanged, as expected given the consistency of the tumor 
encountered intraoperatively [Figure 3].
Pathology and postoperative course
Final pathology confirmed PA, negative for BRAF mutation 
or rearrangement, and the patient was started on combination 
therapy with carboplatin and vincristine. Unfortunately, 
chemotherapy was complicated with breakthrough seizures 
and brain MRI revealed symptomatic interval progression 
of the left midbrain tumor. Carboplatin and vincristine were 
discontinued, and seizures controlled with levetiracetam, 
gabapentin, and valproic acid. e patient was subsequently 
started on a 3 day monthly cycle of cisplatin and etoposide.
On May 2018, 14 months after the first operation, the patient 
presented to the emergency department for worsening 
headache, double vision, right-sided weakness, and gait ataxia. 
Clinically, he was noted to have significant right upper extremity 
weakness to 1–2/5, hypophonia, and rapidly progressing 
functional decline. Brain CT showed known mass extending 
from the brainstem to the thalamus, slightly eccentric on the 
left. A hemorrhagic component within the mass and slight 
increase in size of the tumor was noted as well [Figure 4].
Second operation
e patient underwent suboccipital-torcular craniotomy 
with utilization of volumetric image guidance, microscope, 
and neuromonitoring. e lesion was approached through 
the supracerebellar infratentorial corridor through the 
infracollicular safe entry zone. Initially, the cystic portion was 
decompressed and motor oil-like fluid evacuated. e cyst 
walls collapsed and the brainstem relaxed. e solid portion 
of the tumor in the middle of the caudal midbrain and upper 
pons was considerably softer than in the first surgery, but 
more vascular with areas of hemorrhagic transformation. is 
Figure  3: MRI images with contrast: (a) Immediate preoperative 
axial T1 views; (b) intraoperative Axial T1 views demonstrate 
an approximate 40% resection of the lesion (dotted arrow) and 
expected intraoperative pneumocephalus (solid arrows); (c) 




Figure  4: Four months after partial resection and shunting; 
(a) non-contrast brain CT shows hemorrhagic component 
mostly in the posterior aspect of the tumor; (b) axial, 
(c) sagittal, and (d) coronal T1 MRI views with contrast, 
showing significant interval tumor enlargement with solid 
(solid arrows) and cystic (dotted arrows) components. 
At this point in the patient’s care, it was felt, he did not have many 
options left. He appeared to have either poorly tolerated, or did not 
respond to, chemotherapy. After two prior radiation treatments, he 
was ineligible for further radiation. erefore, a multi-disciplinary 
decision was made to repeat neurosurgical intervention in an attempt 
to decompress the cyst and remove some more tumor, if feasible.
dc
ba
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tumor was successfully mobilized and grossly resected with 
what appeared to be normal appearing brainstem underneath.
Postoperative brain MRI demonstrated GTR and marked 
decompression of the brainstem. Pathology confirmed 
mainly necrosis and hemorrhage with focal residual PA 
with little/no proliferation and Ki-67 in MID1 proliferation 
indices [Figure 5].
Postoperative complications
Five days after surgery, the patient experienced increased 
somnolence. Head CT revealed new bilateral parieto-
occipital subdural and epidural retrocerebellar hemorrhage. 
e parieto-occipital convexity hemorrhages were 
likely related to intra- and postoperative brain shift and 
tearing of the bridging veins. Although supratentorial 
hematomas were not felt to require surgical intervention, 
the retrocerebellar hemorrhage was more significant. e 
patient was subsequently taken up for emergent re-opening 
of the torcular-suboccipital craniotomy for evacuation of the 
epidural hematoma. Postoperative CT revealed successful 
evacuation of the extra-axial hematoma.
ree months after surgery, follow-up brain MRI 
demonstrated evolving postoperative changes with no 
residual/recurrent tumor.
Twelve months after surgery, the patient’s dysarthria 
improved. Motor exam revealed persistent right hemiparesis 
(improved to 3–4/5), arm weaker than the leg. Patient was 
now able to stand and walk short distances with assistance. 
Chronic steroids have been successfully weaned off, and the 
patient had a complete reversal of cushingoid appearance.
DISCUSSION
LGG have been described according to the WHO, as Grades 
I and II.[7] Among these LGGs, the most common primary 
brain tumor is PA described as a relatively benign Grade I 
neoplasm.[7] e most common clinical presentation of 
brainstem PA is a focal neurological deficit of cranial nerves 
corresponding to the anatomical location of the tumor with 
or without involvement of the motor/sensory long tracts.[2] 
Additional symptoms of hydrocephalus and headache may 
be present as well.[2] While PAs are considered to have an 
excellent prognosis with overall 10-year survival reported 
over 90%, tumors where complete surgical resection is 
unable to be carried out have less favorable PFS and overall 
survival.[3,9] In addition, brainstem PA is complicated with 
significant neurological morbidity secondary to their 
location.[11]
e gold standard for approaching pediatric brainstem LGGs 
is initial treatment with safe maximal surgical resection, in 
conjunction with chemotherapy and radiation therapy as 
needed.[11] Upadhyaya et al. studied 25 cases of pediatric 
non tectal brainstem LGGs treated with surgical resection. 
All three patients with GTR and histological diagnosis of PA 
demonstrated no evidence of disease at long-term follow-
up.[11] Overall, the study found a 10-year PFS rate of 71% in 
these 25 patients, of which 16 were cases of brainstem PA.[11]
Kestle et al.’s study investigated 28 cases of pediatric 
brainstem PA, of which 25 were treated with neurosurgical 
resection.[5] Kestle et al.’s study found a direct correlation 
between extent of tumor resection and long-term survival.[5] 
Twelve patients had postoperative imaging demonstrating 
GTR or linear enhancement, with a 10-year PFS of 62%. In 
contrast, the 13 patients with postoperative scans revealing 
residual solid tumor only had a 10-year PFE of 19%.[5] While 
patients with GTR saw long-term PFS, surgical resection 
was often associated with neurological dysfunction most 
apparent in the immediate postoperative phase.[5] is deficit 
typically resolved but persisted in 6 of the 28 patients.[5]
While GTR of brainstem PA clearly leads to favorable 
outcomes, adjuvant or neoadjuvant radiation therapy may 
also be used in the management of these tumors. Gagliardi 
Figure 5: Postoperative brain MRI: (a) Axial T1 image; (b) sagittal T1 image; and (c) coronal T1 image, demonstrating postsurgical changes 
after GTR of the left dorsal midbrain-pontine tumor.
cba
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et al. investigated the use of radiotherapy for LGGs in 39 
patients.[4] Of these, four solid lesions converted into mixed 
tumors following GKRS.[4] In addition, tumor progression 
was followed in patients and found cyst progression occurred 
more commonly in patients with a mixed lesion at the time 
of radiation therapy.[4] Four of five reported incidents of cyst 
progression were found to be PA.[4] Overall, this study found 
a 10-year PFS rate of 39.1% in those treated with Gamma 
Knife Radiosurgery.[4]
e patient in this case report was not offered surgery as 
the first line of treatment. Instead, he was treated with 
SRS, another hypofractionated course of radiotherapy, 
and chemotherapy. It is conceivable that the tumor could 
acquire its very firm consistency as a consequence of these 
treatments. Hardening of the tumor due to radiation therapy 
is a well described phenomenon.[10] Multiple authors reported 
surgical challenges associated with resection of previously 
irradiated tumors. Changes in the tumor consistency might 
be related to the development of fibrosis within the tumor 
and excessive perifocal scarring. Such changes were noted 
during the first surgery. However, the second round of 
chemotherapy with carboplatin and vincristine, along with 
another cycle with cisplatin and etoposide, was associated 
with considerable softening of the tumor and its partial 
hemorrhagic transformation that allowed for gross resection. 
is phenomenon has not been previously described in the 
literature. It could be also suggested that between [Figures 3 
and 4], a newly enhancing tissue (best seen on the axial and 
coronal MR images) may represent a growth of radiotherapy-
naïve tumor, which was softer and thus, more amenable to 
surgical resection. is hypothesis can be true only if the 
surgeons did not leave behind a considerable amount of solid 
tissue after the first surgical procedure, which was not the 
case. In addition, the tumor, new or old, could outgrow its 
blood supply and undergo necrotic transformation, which 
could also be influenced by chemotherapy. It is important to 
note, though, that the new radiotherapy-naïve component 
was exposed to chemotherapy, much like the hard tumor 
treated with XRT. At this point, we can only speculate about 
the extent to which the above potential mechanisms could 
have contributed to the apparent softening of the mass. 
Although not unequivocally proving the exact causality, 
the facts that remain clear are (1) very hard consistency of 
the tumor discovered on the first surgery and (2) a quite 
significant softening of previously unresectable lesion 
after chemotherapy. erefore, the authors believe that 
chemotherapy could have contributed to the success of the 
second surgery.
We did not find any reports of repeat surgical interventions 
on adult patients with brainstem LGG. One study reported 12 
pediatric patients with midbrain LGG who were treated with 
multiple repeat tumor resections due to disease progression 
with seemingly stable long-term results obtained in at least 
nine patients.[8] e surgeons treating brainstem LGG should 
be aware of possibility of chemotherapy induced tumor 
softening phenomenon and be prepared to offer repeat 
surgery, even if the lesion was initially deemed unresectable.
CONCLUSION
Aggressive treatment of brainstem LGG should be 
pursued whenever possible, given its generally favorable 
prognosis. Repeat microsurgical resection, even with a 
different approach, might be reasonable and safe. Finally, 
chemotherapy may be associated with changes in the tumor 
consistency that can render previously unresectable lesions 
amenable to successful aggressive resection.
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